JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
On Thursday, Jefferies analyst Laurence Alexander revised the price target for Ashland Inc . (NYSE: NYSE:ASH) shares, reducing it to $82.00 from the previous $92.00. Despite the adjustment, the firm maintains a Buy rating on the stock. The revision comes as the stock trades near its 52-week low of $56.46, having declined 16.3% year-to-date. According to InvestingPro analysis, Ashland appears undervalued at current levels. Alexander’s (NYSE:ALX) commentary pointed to several factors impacting Ashland’s business outlook. He noted that while destocking might not pose an immediate concern, a dip in consumer confidence could become an incremental challenge, particularly for the sales in the personal care segment. Despite these challenges, InvestingPro data reveals the company maintains strong financial health with a current ratio of 2.52, indicating robust liquidity to meet short-term obligations.
The analyst also suggested that Ashland’s margins could benefit from productivity and a favorable product mix, as raw material costs are expected to remain stable. However, Alexander’s projections for Ashland’s financial performance in the coming years are somewhat cautious. His estimates for the company’s 2025 and 2026 earnings are approximately 5% below the consensus. Notably, InvestingPro highlights that management has been actively buying back shares, demonstrating confidence in the company’s future, while maintaining an impressive 55-year streak of consistent dividend payments, currently yielding 2.73%.
Alexander’s analysis indicates that Ashland stock may experience limited movement in the near term. He anticipates the shares will stay range-bound until there is more certainty and stability in earnings revisions. This outlook is based on the current economic signals and the company’s specific market challenges.
Ashland Inc. is a global specialty chemicals company that serves a wide range of industries, including personal care, pharmaceuticals, and construction. The company’s financial health and stock performance are closely watched by investors who rely on the insights provided by industry analysts like those at Jefferies.
The updated price target and maintained Buy rating reflect Jefferies’ current view on Ashland’s potential despite the noted headwinds. As the market digests this information, investors will monitor how Ashland’s stock responds to these revised expectations.
In other recent news, Ashland Inc. reported mixed results for its first-quarter earnings for fiscal year 2024. The company achieved an adjusted earnings per share (EPS) of $0.28, surpassing the forecast of $0.24, but missed its revenue forecast by reporting $405 million against an expected $431.72 million. This revenue shortfall, alongside a 14% decline in sales compared to the previous year, has highlighted ongoing challenges in the market environment. BMO Capital Markets responded by lowering Ashland’s price target from $84.00 to $77.00, although it maintained a Market Perform rating. Concerns primarily stem from the Life Sciences segment, with uncertainties about the timing of a broader organic recovery. Seaport Global Securities also adjusted its stance on Ashland, downgrading the company from a Buy to a Neutral rating due to competitive pressures in the Specialty Additives market in China. Despite these challenges, Ashland is actively pursuing manufacturing optimization and strategic initiatives to stabilize pricing and volumes by fiscal year 2025. The company reaffirms its full-year sales guidance of $1.9 billion to $2.05 billion, supported by new product launches and cost-saving measures targeting $90 million.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.